Faced with a monkeypox vaccine supply and demand problem, the White House’s newly minted National Monkeypox Response team on Tuesday implemented a plan to stretch the current vaccine supply by up to five-fold.
The U.S. Food and Drug Administration on Tuesday issued an emergency use authorization (EUA) for the Jynneos monkeypox vaccine to be administered by intradermal injection, which requires one-fifth of the dose of a normal subcutaneous injection.
“In recent weeks the monkeypox virus has continued to spread at a rate that has made it clear our current vaccine supply will not meet the current demand,” said FDA Commissioner Dr. Robert Califf in a statement….